Critical period for a teratogenic VLA-4 antagonist: Developmental effects and comparison of embryo drug concentrations of teratogenic and non-teratogenic VLA-4 antagonists.
Crofts F, Rohatagi S, Pino M, DeLise B, Zhang J, Nguyen M, Guittin P, Barbellion S, Brunel P, Hofmann T, Schmidt J, Wong M, Lockey P, Lerman S, Clark R.
Birth Defects Res B Dev Reprod Toxicol. 2004 Apr;71(2):69-79.PMID: 15098200 [PubMed - indexed for MEDLINE]Related articles